Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL659625 | 0.98 | CYP3A4 (0.35) | CYP3A4CYP2D6TSHRESR1ESR2 | |
| SCHEMBL14829981 | 0.77 | SIGMAR1 (0.32) | — | |
| SCHEMBL14833298 | 0.77 | SIGMAR1 (0.32) | — | |
| SCHEMBL14833320 | 0.77 | SIGMAR1 (0.32) | — | |
| SCHEMBL14833275 | 0.76 | — | — | |
| SCHEMBL16321799 | 0.76 | — | — | |
| SCHEMBL14833274 | 0.76 | — | — | |
| SCHEMBL14833352 | 0.76 | — | — | |
| SCHEMBL16321798 | 0.76 | — | — | |
| SCHEMBL659964 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | claimed |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | UNIV VANDERBILT (US) | 2017-11-09 | — | — | US | disclosed |
| US-9453017-B2 | Antiviral therapies with phospholipase D inhibitors | VANDERBILT UNIVERSITY (US) | 2016-09-27 | — | — | US | disclosed |
| EP-2931277-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | Vanderbilt University (US) | 2015-10-21 | — | — | EP | disclosed |
| US-20150025041-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2015-01-22 | — | — | US | disclosed |
| US-20140378524-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY | 2014-12-25 | — | — | US | disclosed |
| EP-2760447-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | Vanderbilt University (US) | 2014-08-06 | — | — | EP | disclosed |
| WO-2014093557-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2014-06-19 | — | — | WO | disclosed |
| WO-2013049773-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | VANDERBILT UNIVERSITY (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378524-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | CYP3A4 4058/4885CYP2D6 3928/4885TSHR 3721/4885 |
| US-20170319611-A1 | METHODS AND COMPOSITIONS COMPRISING AKT INHIBITORS AND/OR PHOSPHOLIPASE D INHIBITORS | PLD1, PLD2, PIK3CD | CYP3A4 4058/4885CYP2D6 3928/4885TSHR 3721/4885 |
| US-20150025041-A1 | ANTIVIRAL THERAPIES WITH PHOSPHOLIPASE D INHIBITORS | PLD1, PLA2G2D, PLD2 | CYP3A4 2317/4885CYP2D6 1520/4885TSHR 3636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.